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Abstract
Background: CAR/RXR heterodimers bind a variety of hormone response elements and activate
transcription in the absence of added ligands. This constitutive activity of murine CAR can be
inhibited by the inverse agonist ligand androstanol or increased by the agonist TCPOBOP. RXR
agonists activate some RXR heterodimer complexes, which are termed permissive, while other
non-permissive complexes are not responsive to such ligands.
Results: Direct protein-protein interaction studies demonstrate that the RXR agonist 9-cis-RA
increases interaction of CAR/RXR heterodimers with the coactivator SRC-3, but also inhibits the
ability of TCPOBOP to increase and androstanol to decrease coactivator binding. CAR
transactivation of a response element with a five nucleotide spacer (DR-5) is unaffected by 9-cis-
RA or the synthetic RXR agonist LG1069. In agreement with the inhibitory effect observed in vitro,
these rexinoids block both the TCPOBOP mediated transactivation of this element and the
androstanol dependent inhibition. In contrast, CAR transactivation of other response elements is
increased by rexinoids. Stable expression of CAR in a HepG2 derived cell line increases expression
of the endogenous CAR target CYP2B6. This expression is further increased by TCPOBOP but
decreased by either androstanol or LG1069, and LG1069 blocks the stimulatory effect of
TCPOBOP but not the inhibitory effect of androstanol.
Conclusion: We conclude that CAR/RXR heterodimers are neither strictly permissive nor non-
permissive for RXR signaling. Instead, rexinoids have distinct effects in different contexts. These
results expand the potential regulatory mechanisms of rexinoids and suggest that such compounds
may have complex and variable effects on xenobiotic responses.
Background
At least one third of the 48 human members of the
nuclear hormone receptor superfamily function as het-
erodimers with the Retinoid X Receptors, (RXRs, NR2B1-
3) [1]. Some, but not all of these heterodimers can be
directly activated by RXR agonists, called rexinoids, which
include the endogenous ligand 9-cis-retinoic acid (9-cis-
RA) and a number of synthetic compounds. The rexinoid
responsive complexes are referred to as permissive and
include the Peroxisome Proliferator Activated Receptor
(PPAR) and the Farnesoid X Receptor (FXR) heterodimers;
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the Retinoic Acid Receptor (RAR), and Thyroid Hormone
Receptor (TR) heterodimers are non-permissive [2–7].
The xenobiotic receptor CAR (NR1I3) [8,9] is one of sev-
eral RXR heterodimers that has not been assigned to either
category. Initial results showed that CAR is an apparently
constitutive transactivator able to activate gene expression
in the absence of exogenously added ligands [8,9]. The
first CAR ligands identified, androstanol and androstenol,
are inverse agonists that block this constitutive transacti-
vation [10]. More recently, it has been found that CAR
mediates the characteristic response of a subset of drug
metabolizing enzymes to a variety of structurally unre-
lated foreign compounds [11]. These xenobiotic activators
are referred to as "phenobarbital (PB) – like," based on
the prototypic effects of the anti-epileptic agent on drug
metabolism [12–14]. The most potent activator of murine
CAR is the high affinity agonist ligand TCPOBOP (1,4-bis
[2-(3,5-dichloropyridyloxy)]benzene) [15,16].
The effects of specific RXR ligands on the CAR/RXR het-
erodimer have not been characterized, although high con-
centrations of both 9-cis-RA and all-trans retinoic acid
have been reported to block PB induction of the CAR tar-
gets CYP2B1 and CYP2B2 in primary rat hepatocytes [17].
In addition, a recent report suggests that both compounds
decrease TCPOBOP-dependent CAR transactivation [18].
In both cases, these effects were primarily attributed to
sequestration of limiting amounts of RXR into ligand-
dependent homodimers or heterodimers with other
receptors.
We have used several approaches to specifically examine
the responsiveness of the CAR/RXR heterodimer to rexi-
noids. Unexpectedly, different responses were observed
using different methods. Direct biochemical measure-
ments demonstrate that rexinoids can induce coactivator
binding, but can also inhibit the effects of CAR agonist
and inverse agonist ligands. In transient transfections, the
presence of RXR ligands can also inhibit the effects of
these CAR ligands. However, different CAR/RXR het-
erodimer binding sites show distinct responses to RXR
activation. Overall, these results significantly increase the
potential complexity of the response of RXR heterodimers
to RXR ligands and suggest a potential modulatory effect
of rexinoids on xenobiotic responses.
Results
RXR ligands block effects of CAR agonist and inverse ago-
nist ligands on coactivator binding in vitro
Initial functional results suggested that transactivation by
CAR/RXR heterodimers is not affected by RXR ligands,
including 9-cis-RA or synthetic rexinoids, indicating that
CAR is a non-permissive RXR partner. However, gel shift
studies indicated that the mobility of the CAR/RXR com-
plex bound to a DR-5 element is increased by the presence
of 9-cis RA, suggesting that the RXR ligand can bind to the
CAR/RXR heterodimer. An increase in the mobility of the
CAR/RXR complex was also observed in the presence of
TCPOBOP or androstanol, alone or in combination with
9-cis RA (data not shown).
To test the effects of rexinoids on coactivator binding in a
defined biochemical system, surface plasmon resonance
was used to characterize the effects of the various ligands
on binding of CAR, RXR and CAR/RXR heterodimers to
SRC-3 (also known as ACTR, p/CIP, RAC3, AIB1, TRAM-
1), an effective coactivator for CAR and many other mem-
bers of the nuclear receptor superfamily. As expected, 9-
cis-RA stimulated coactivator binding to RXR alone, and
the basal interaction of CAR with SRC-3 was enhanced by
TCPOBOP and decreased by androstanol (Fig. 1A,1B).
The interaction of SRC-3 with the preformed and charac-
terized CAR/RXR heterodimer complex was increased by
either TCPOBOP or 9-cis-RA (Fig. 1C). Strikingly, how-
ever, coactivator binding to the heterodimer complex was
decreased below the basal level in the presence of both lig-
ands. In addition, SRC-3 binding to the heterodimer was
decreased by androstanol and this effect was largely
blocked by 9-cis-RA. These effects of 9-cis-RA on coactiva-
tor binding to the preformed heterodimer contrast with
the strong stimulatory effect observed with RXR alone,
confirming the characterization of this complex. These
results demonstrate that the presence of the RXR ligand
can significantly alter the response of the CAR/RXR het-
erodimer to CAR ligands.
Effects of rexinoids on CAR responses to agonist and 
inverse agonist ligands in cells
To examine the effects of RXR ligands on CAR transactiva-
tion in a more functional context, the rexinoid LG1069
was combined with the CAR inverse agonist androstanol
and the agonist TCPOBOP in a series of transient transfec-
tion studies using different response elements. Initial
studies were based on a well characterized binding site for
CAR/RXR heterodimers, the DR-5 element from the pro-
moter of the retinoic acid receptor β2 isoform [8,9,16]. In
agreement with the biochemical results, the rexinoid
blocked both the stimulatory effect of the agonist and the
inhibitory effect of the inverse agonist on this element
(Fig. 2A). In more detailed dose response studies, 100 nM
LG1069 decreased the inhibitory effect of androstanol by
as much as 70% and had an even stronger effect on
TCPOBOP activation (Fig. 2B). Consistent with previous
results [9], deletion of the helix 12 AF-2 motif of CAR
eliminated both constitutive and ligand dependent trans-
activation. Deletion of the same motif in RXR also
strongly decreased transactivation, but did not completely
eliminate ligand responses (Fig. 2A).Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/2
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To test whether the apparent allosteric effects of LG1069
on CAR transactivation vary with different response ele-
ments, the effect of the rexinoid on transactivation
directed by cytochrome P450 response elements was
examined. In contrast to the results with the DR-5 site, but
in agreement with the biochemical results, LG1069 alone
had a stimulatory effect on the ER-6 CAR response ele-
ment from the promoter of the CYP3A4 gene (Fig. 3). This
effect was not due to RXR homodimer function, since no
transactivation was observed with RXR alone. In contrast
to both the DR-5 and biochemical results, LG1069 did not
block the stimulatory effect of TCPOBOP. Instead, the
stimulatory effect of the two agonists was retained when
they were combined. Combining LG1069 with the inverse
agonist androstanol resulted in a partial block in its inhib-
itory effect and an intermediate level of activity. Similar
results were observed with the tandem DR-4 sites from the
CYP2B10 gene, except that LG1069 did not have a signif-
icant stimulatory effect on its own, but did augment the
effect of TCPOBOP. It is interesting that these two CYP
elements respond somewhat differently to RXR cotrans-
fection, which increases responses directed by the
CYP3A4 element but modestly decreases responses of the
CYP2B10 element (data not shown). On both elements,
similar results were observed when 9-cis RA was substi-
tuted for LG1069 (data not shown). These results show
that the negative effects of rexinoids on TCPOBOP and
androstanol signaling observed with the DR-5 site from
the RARβ promoter are not observed with the DR-4 and
ER-6 sites from the CYP promoters. Thus, the CAR/RXR
heterodimer responds differently to retinoids on different
elements.
Figure 1
9-cis RA blocks effects of CAR ligands on coactivator binding in vitro. GST-SRC-3 fusion protein was immobilized on 
a flow cell and tested for interaction with receptors. A. Overlaid results of injections of apo-RXR and RXR preincubated in the 
presence of 9-cis RA. B. Overlaid results of injections of apo-CAR and CAR preincubated in the presence of TCPOBOP (TC) 
or androstanol (An). C. Overlaid results of injections of preformed CAR/RXR heterodimers preincubated in the presence or 
absence of 9-cis RA and TCPOBOP (TC) as indicated. D. Overlaid results of injections of preformed CAR/RXR heterodimers 
preincubated in the presence or absence of 9-cis RA and androstanol (An) as indicated.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/2
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Figure 2
The RXR ligand LG_1069 blocks effects of CAR ligands. A. HepG2 cells were cotransfected with vectors expressing 
wild type CAR (CAR wt), a CAR AF-2 deletion mutant (CAR∆8) or an RXR AF-2 deletion mutant (RXR∆19), together with a 
luciferase reporter containing the βRARE response element, in the presence or absence of androstanol, TCPOBOP and/or 
LG1069. Luciferase activity is relative to that directed by CAR alone (100%). B. A CAR expression vector was cotransfected 
into HepG2 cells with the βRARE-TK-Luc reporter construct in the presence of solvent (open squares) or 100 nM LG1069 
(solid diamonds) and increasing amounts of either androstanol or TCPOBOP as indicated. Luciferase activity is relative to that 
in the absence of ligand (100%).Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/2
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Rexinoid inhibition of agonist activation of an endogenous 
CAR target gene
A previously described HepG2 derivative stably expressing
mouse CAR [16] was used to determine the effects of RXR
agonists on CAR function in the context of native chroma-
tin. Expression of CYP2B6, a human relative of CYP2B10,
is constitutively induced in this cell line. In contrast to the
results with the transient transfections with the CYP
response elements, CYP2B6 expression was decreased to a
comparable extent by androstanol, LG1069, and the com-
bination of both ligands. CYP2B6 expression was
increased by TCPOBOP, as expected, and this response
was blocked by LG1069 treatment.
Discussion
A number of RXR heterodimer complexes have been cate-
gorized as either permissive or non-permissive based on
their responses to RXR ligands [1]. Although there are
some reported discrepancies, the PPAR, FXR and NGF-IB/
NURR1 complexes are generally considered permissive,
while the non-permissive group includes the RAR, TR and
VDR complexes (see [2–7]). In the permissive complexes,
coactivators can presumably bind to the AF-2 surface of
both partners and binding to the RXR partner is stimu-
lated by rexinoid agonists. This can result in distinct
responses depending on which of the two partners is acti-
vated. In the case of the PPARγ/RXR complex, for example,
activation with PPAR or RXR specific ligands results in
recruitment of quite different coactivators [19].
Among the non-permissive complexes, the RAR/RXR het-
erodimer is the best studied. Recent results suggest that
the C-terminal helix 12 of RXR exerts allosteric effects on
RAR function [6]. However, additional studies suggest
that corepressor binding to the apo-RAR component of
the heterodimer blocks rexinoid induced binding of coac-
tivators to RXR [7]. These results suggest that the mecha-
nisms that account for the lack of responsiveness of the
non-permissive complexes are complex.
As summarized in Fig. 5, the results described here dem-
onstrate that the effects of RXR agonists on the CAR/RXR
heterodimer can be quite different in different contexts. In
vitro studies in the absence of DNA demonstrate that CAR/
RXR heterodimers can be activated by an agonist ligand
for either receptor. This positive response to 9-cis-RA con-
trasts with the inhibition that would result from the loss
of RXR to ligand-dependent homodimers [20],
Figure 3
Rexinoid effects on CAR/RXR are dependent on response element. A. HepG2 cells were cotransfected with expres-
sion constructs for CAR and/or RXR together with a previously described luciferase construct containing a ER-6 type element 
from the, human CYP3A4 promoter [16] in the presence or absence of ligands. The luciferase activity presented above is rela-
tive to that directed by vector alone in the absence of ligands (100%). B. A similar transfection with a previously described 
reporter containing the tandem DR-4 elements from the mCYP2B10 gene [16].Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/2
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confirming that these studies reflect the activity of CAR/
RXR heterodimers and demonstrating that such com-
plexes can be permissive for RXR signaling. Remarkably,
however, coactivator binding is decreased in the presence
of both of the activating ligands. Similarly, the inhibitory
effect of the inverse agonist ligand androstanol on coacti-
vator recruitment is blocked by 9-cis-RA.
In transient transfections, the rexinoid LG1069 shows dif-
ferent effects on the ability of the xenobiotic receptor to
transactivate various response elements. The rexinoid
alone has no effect on transactivation of the βRARE, but
strongly inhibits responses to both the agonist TCPOBOP
and the inverse agonist androstanol. In contrast, LG1069
can stimulate transactivation of the response element
from the CYP3A4 promoter. On that element it does not
block the stimulatory effect of TCPOBOP, but decreases
the inhibitory effect of the androstanol somewhat. On the
tandem CYP2B10 elements, LG1069 does not have a
stimulatory effect on its own and does not decrease the
inhibitory effect of androstanol, but it does increase
response to TCPOBOP. Finally, expression of the endog-
enous CYP2B6 gene in CAR expressing HepG2 cells is
modestly inhibited by LG1069 alone, androstanol alone
and the combination of both. In this context, the rexinoid
blocks activation by the agonist TCPOBOP.
These rexinoid responses share the general theme of inhi-
bition of some of the effects of CAR ligands by RXR lig-
ands, but are clearly quite disparate. The differences may
be based on variations in experimental approach or on
more fundamental functional differences. For example, it
is possible that the inhibitory effect of LG1069 in the sta-
ble CAR expressing cell line is based on the sequestration
of limiting amounts of RXR into ligand-dependent
homodimers, as has been suggested in previous studies
using primary hepatocytes [17]. However, similar effects
were observed with the relatively large amounts of RXR
used for the biochemical studies or with the transient
transfections, which relied on cotransfected RXR. It is also
possible that differences in the chromatin context could
contribute to the differences between the effects observed
with the endogenous and transiently transfected promot-
ers. However, such differences cannot account for the
results with reporter plasmids that differ only in the iden-
tity of the response element. Overall, we conclude that
binding of both the DNA and the RXR ligands can result
in allosteric effects on the function of the CAR/RXR
heterodimer.
The disparities in these responses preclude a single, sim-
ple explanation for the effects of rexinoids on CAR/RXR
heterodimers. Nonetheless, one attractive possibility is
Figure 4
Rexinoid effects on expression of CYP2B6 in mCAR 
expressing HepG2 cells. Total RNA was prepared from a 
previously described HepG2 derivative stably expressing 
mCAR [16] and cultured in the presence of the indicated lig-
ands (An, androstanol; LG, LG1069; TC, TCPOBOP) for 9 
hours. Expression of CYP2B6 and the EF1α control was ana-
lyzed by northern blotting using appropriate cDNA probes 
and quantitated by phosphorimager analysis. Very similar 
results were obtained in 3 independent experiments; a rep-
resentative experiment is shown
Figure 5
Diverse effects of rexinoids on CAR/RXR activities. 
The effects of rexinoids on basal and CAR ligand dependent 
transactivation are summarized. Upward and downward 
arrows indicate stimulation and inhibition of coactivator 
binding or transcriptional effects. The rightward bar (----|) 
symbolizes a blockage of the effect of the CAR ligand by rex-
inoids (or decrease in the case of the repression of the CYP 
elements by androstanol); (-), no effect.Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/2
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that binding of the RXR agonist exerts direct inhibitory
effects on either the binding or functional effects of the
CAR ligands. Some precedence for a significant allosteric
effect of one heterodimer partner on another is provided
by the inability of the insect ecdysone receptor to bind its
steroid ligand in the absence of its heterodimer partner
USP [21].
The outcome of this inhibition of CAR ligand binding
would be somewhat different depending on whether or
not the RXR agonist was able to activate the basal transac-
tivation of CAR/RXR heterodimer bound to a particular
element. On the βRARE, for example, the RXR agonist
might bind, but not increase transactivation beyond that
observed in the absence of ligands. In this case, blocking
TCPOBOP binding would strongly inhibit TCPOBOP-
dependent transactivation. In the case of the CYP3A4
response element, however, activation by the RXR agonist
is comparable to that observed with TCPOBOP alone.
Thus, blocking TCPOBOP binding would not result in the
net inhibitory effect observed with the βRARE, but could
account for the lack of additive effect of the two ligands.
A variety of factors complicate this relatively simple
model, including the specific cytoplasmic to nuclear
translocation that is required for CAR transactivation in
the liver [22,23]. Rexinoids by themselves are apparently
unable to induce this translocation process in rat [17] or
mouse (data not shown) hepatocytes and thus cannot
directly activate CAR targets. More complex combinatorial
effects of other coactivators or corepressors (e.g. [6,7])
could also contribute to the observed responses. Recent
results suggest that CAR can interact with NCoR or SMRT
in the presence of inverse agonists [24], although such
interactions appear much weaker than those of other
receptors. Further characterization of potential CAR cofac-
tors, as well as the development of sensitive and direct
ligand binding assays will be required to define the molec-
ular mechanisms that account for the diverse effects of
rexinoids on CAR transactivation.
Conclusions
Overall, we conclude that the disparate effects of rexinoids
on CAR/RXR heterodimers in different contexts add sig-
nificantly to the potential complexity of the effects of RXR
ligands on such nuclear receptor heterodimers, and dem-
onstrate that classifying a particular complex as permis-
sive or non-permissive can be an oversimplification. The
results described here also suggest that rexinoids may have
modulatory effects on xenobiotic responses, and that such
effects may differ for different CAR/RXR target genes. A
systematic examination of the effects of RXR ligands and
retinoid status on a number of the growing set of CAR tar-
get genes will be required to explore this possibility.
Materials and Methods
Surface plasmon resonance
The effect of ligands on coactivator binding was evaluated
using the BIAcore instrument as described [25,26]. For
interaction of CAR, RXR and CAR/RXR heterodimer with
SRC-3, a GST-SRC-3 fusion protein containing the recep-
tor interaction domain of the coactivator was expressed in
bacteria and purified. This fusion protein was immobi-
lized in flow cells using anti-GST antibody. Lack of bind-
ing of free GST demonstrated that the surface was
saturated with GST-SRC3. Purified CAR and RXR proteins
were produced in bacteria and preincubated overnight at
4°C alone or in combination, and in the presence or
absence of 10-5M androstanol, 10-6M TCPOBOP, 10-6M of
9 cis-RA, as appropriate. CAR alone, RXR alone, and CAR/
RXR heterodimers bound to various ligands were injected
individually into flow cells and binding was measured as
described [25,26].
Plasmids
The βRARE-TK-Luc reporter plasmid with three copies of
the DR-5 motif from the promoter of the mouse RARβ2
gene has been described previously, as has the CYP2B10-
TK-Luc reporter with two copies of the DR-4 type elements
from the promoter of the mouse CYP2B10 gene and the
CYP3A4-TK-luc reporter with three copies of the ER-6 ele-
ment from the human CYP3A4 promoter [16]. Expression
vectors for full length mCAR and RXR proteins were as
described [9]. The cdm8-mCAR∆8 deletion construct con-
taining a deletion of the last 8 amino acids and the mutant
with 2 helix 3 mutations (F171L, I174A) that block ligand
binding and response have been described previously
[16], as has the cdm8-RXR∆19 construct with a deletion of
the last 19 amino acids [3].
Cell culture and transfections
HepG2 cells were maintained in Dulbecco's modified
Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (Hyclone). For transfections, 105 HepG2
cells were plated in 24 well dishes with DMEM supple-
mented with 10% charcoal stripped serum and trans-
fected using the calcium phosphate precipitation method
as described [16]. The next morning, cells were washed
with phosphate buffered saline and ligands were added.
Typically, transfections included 100–200 ng of luciferase
reporter plasmids, 100 ng of β-galactosidase (β-gal) inter-
nal control plasmid (CMV β-Gal), and 100 ng of cdm8
expression vectors. A total of 500 ng of plasmids was used
per well. Cells were assayed for luciferase (Promega) activ-
ities 24 hours after addition of ligands and reporter
expression was normalized to β-galactosidase activity
(Tropix) according to the manufacturer's directions. Simi-
lar results were obtained from at least three independent
experiments. Error bars are included for experiments
where variations were more than 10%. A previouslyPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/2
Page 8 of 8
(page number not for citation purposes)
described derivative of HepG2 cells stably expressing
mCAR [16] was used for RNA analysis. Cells were subcul-
tured and incubated in DMEM supplemented with 10%
charcoal stripped bovine serum overnight. Various lig-
ands were added and total RNA was prepared 9 hours later
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